Diagnosis of protein C deficiency in patients on oral anticoagulant treatment: comparison of three different functional protein C assays

Thromb Haemost. 1990 Jun 28;63(3):407-12.

Abstract

The efficacy of three different protein C activity assays and of protein C antigen determination for the diagnosis of protein C deficiency was studied in 13 protein C deficient patients (11 with type I, 2 with type II deficiency) and in 51 presumably non-deficient patients (control group), both groups being on oral anticoagulant (OAC) treatment. For protein C activity measurement (1) the assay according to Francis (slightly modified) with thrombin activation and measurement of activated protein C in the aPTT system, (2) an assay using Protac activation and chromogenic substrate (Protac-CS) and (3) an assay using Protac activation and the aPTT system (Protac-PTT) were used. Protein C antigen was determined by Laurell immunoelectrophoresis. The three activity assays gave different results, with the highest values obtained by the Protac-CS assay and the lowest values by the Protac-PTT assay. The Francis assay gave intermediate results. Protein C activity and antigen values were significantly lower in protein C deficient patients compared to the control group. Protein C activity tests had a higher discriminative power than the antigen determination. After taking into account the intensity of treatment, by the Francis assay all deficient and non-deficient patients were correctly classified, by the Protac-CS and the Protac-PTT assay 2 and 4 patients, respectively, were misclassified and by the antigen assay 8 patients were misclassified. Calculation of the ratios of protein C activity to factor II activity was of high discriminative power. We conclude that for diagnosis of protein C deficiency protein C activity tests are superior to antigen determination not only in type II but also in type I deficient patients.(ABSTRACT TRUNCATED AT 250 WORDS)

Publication types

  • Comparative Study

MeSH terms

  • 4-Hydroxycoumarins / therapeutic use*
  • Administration, Oral
  • Humans
  • Immunoelectrophoresis
  • Phenprocoumon / therapeutic use*
  • Predictive Value of Tests
  • Protein C / metabolism
  • Protein C Deficiency*
  • Thrombosis / blood
  • Thrombosis / drug therapy
  • Thrombosis / genetics*

Substances

  • 4-Hydroxycoumarins
  • Protein C
  • Phenprocoumon